南模生物(688265) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥85,440,761.93, representing a year-on-year increase of 25.78%[5] - The net profit attributable to shareholders was -¥4,959,326.26, a decrease of 108.15% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥12,643,704.76, reflecting a decline of 124.09%[6] - Basic earnings per share for the current reporting period was -105.77, with diluted earnings per share also at -105.77, reflecting a decrease in net profit[11] - The net profit for Q3 2022 was -75,071.53 RMB, a significant decrease compared to 38,727,634.07 RMB in Q3 2021[25] - The total profit for Q3 2022 was -3,737,828.96 RMB, down from 43,878,279.60 RMB in the same period last year[25] - Operating profit for Q3 2022 was -3,594,726.72 RMB, compared to 44,123,180.62 RMB in Q3 2021[25] - The total comprehensive income for Q3 2022 was 356,678.47 RMB, down from 38,725,802.05 RMB in Q3 2021[26] - Basic and diluted earnings per share for Q3 2022 were both 0.00 RMB, compared to 0.66 RMB in Q3 2021[26] Research and Development - The total R&D investment amounted to ¥21,544,964.23, which accounted for 25.22% of operating revenue, an increase of 4.82 percentage points year-on-year[6] - Total R&D investment for the current reporting period was 55.48 million, an increase from 32.78 million for the year-to-date[11] - Research and development expenses for the first three quarters of 2022 amounted to CNY 44,957,893.67, compared to CNY 33,859,549.58 in 2021, reflecting a year-over-year increase of approximately 32.7%[23] - The company is focusing on expanding its research and development efforts, as evidenced by the increased R&D expenses, which may lead to new product developments in the future[23] Cash Flow and Assets - The cash flow from operating activities was -¥17,163,740.37, indicating a significant decline of 133.77%[6] - The company's cash and cash equivalents decreased to CNY 251,303,400.28 from CNY 1,566,200,232.11, a decline of about 84%[18] - Cash flow from operating activities for the first nine months of 2022 was -17,163,740.37 RMB, a decline from 50,820,389.56 RMB in the same period of 2021[29] - Cash flow from investment activities in the first nine months of 2022 was -1,057,536,533.39 RMB, compared to a positive cash flow of 21,708.78 RMB in the previous year[29] - The cash and cash equivalents at the end of Q3 2022 were 251,278,400.28 RMB, a decrease from 115,526,472.92 RMB at the end of Q3 2021[30] - The company reported a cash inflow from operating activities of 190,703,456.29 RMB for the first nine months of 2022, down from 202,626,670.51 RMB in the same period of 2021[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,008[13] - The largest shareholder, Shanghai Dish Consulting Co., Ltd., holds 27,771,000 shares, representing 35.6% of total shares[13] - The second-largest shareholder, Shanghai Technology Venture Capital Co., Ltd., holds 10,760,733 shares, accounting for 13.8%[13] Operational Challenges - The company faced challenges in revenue growth due to the impact of COVID-19 control measures in Shanghai, affecting new orders and revenue recognition[10] - The company's operating revenue growth was low due to COVID-19 control measures in Shanghai, leading to a decrease in cash inflow from operating activities[11] - The company is facing uncertainties in its external operating environment due to the ongoing impact of COVID-19, which may affect logistics and transportation[16] - The company has implemented enhanced epidemic prevention measures and emergency plans to mitigate the adverse effects of COVID-19[17] Costs and Liabilities - Total operating costs for the first three quarters of 2022 were CNY 234,245,219.39, up from CNY 150,123,769.13 in 2021, indicating a significant increase of about 56%[23] - Total liabilities as of September 30, 2022, were CNY 368,227,444.67, up from CNY 180,396,846.80 in 2021, which is an increase of approximately 103.5%[20] - The company's inventory as of September 30, 2022, was CNY 14,674,652.20, slightly down from CNY 15,011,078.34 in 2021, indicating a decrease of about 2.2%[18] - The non-current assets totaled CNY 676,689,973.38 as of September 30, 2022, compared to CNY 203,350,577.75 at the end of 2021, representing a significant increase of approximately 232%[19] Production Capacity - The company expanded its production capacity from 50,000 cages to 110,000 cages, leading to increased costs in depreciation and material expenses[10] - Management expenses increased significantly due to the new Shanghai Novartis base being in the renovation and trial operation phase, resulting in high rental and utility costs[10]